Lec 3+4 Pharmacology PDF
Document Details
Uploaded by FastestGrowingHawk6345
3rd Year Dental Students
Dr. Duaa Nidhal
Tags
Related
- PHA 300 Pharmacology I: The Autonomic and Somatic Motor Nervous System PDF
- Autonomic Nervous System Introduction PDF
- Introduction to the Autonomic Nervous System (ANS) PDF
- NUR 213 Autonomic Nervous System Drugs PDF
- Lec 4 Pharmacology (Autonomic Nervous) PDF
- General Pharmacology MCQ PDF - 2nd Year Dental, ZU
Summary
These lecture notes cover the topic of pharmacology, specifically the autonomic nervous system. The document details the functions of the autonomic nervous system, and the sympathetic and parasympathetic nervous systems in particular. It also describes their responses to various situations, in comparison to the somatic nervous system.
Full Transcript
3rd Year Dental Students pharmacology Dr. Duaa Nidhal Autonomic Nervous System The nervous system is divided into two anatomical divisions: the central nervous system (CNS), which is composed of the brain and spinal cord, and the peripheral ner...
3rd Year Dental Students pharmacology Dr. Duaa Nidhal Autonomic Nervous System The nervous system is divided into two anatomical divisions: the central nervous system (CNS), which is composed of the brain and spinal cord, and the peripheral nervous system, which includes neurons located outside the brain and spinal cord,that is, any nerves that enter or leave the CNS (figure 1) The autonomic nervous system (ANS) is largely independent (autonomous) in that its activities are not under direct conscious control. It is concerned primarily with visceral functions such as cardiac output, blood flow to various organs, and digestion, which are necessary for life. Figure 1: autonomic nervous system part of nervous system The ANS carries nerve impulses from the CNS to the effector organs by way of two types off efferent neurons: the preganglionic neurons and the postganglionic neurons. In this pre and post ganglionic complex the ganglia function is embodied in acting as relay stations between the preganglionic neuron and the second nerve cell, the postganglionic neuron (figure 2). In the sympathetic system, the preganglionic fibres are short and postganglionic fibres are long. On the other hand, the parasympathetic preganglionic fibres are long and postganglionic fibres are short. 1 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Figure 2: preganglionic and post ganglionic neurons The function of the ANS can be explained by exploring the function of each part as the following (Figure 3): Figure 3: difference between parasympathetic and sympathetic division 2 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Functions of the sympathetic nervous system The effect of sympathetic output is to: 1. Increasing heart rate and contractility, and thus, increasing blood pressure. 2. Constriction of the blood vessels of skin, mucous membranes, and splanchnic area, and dilation of skeletal muscles vessels. 3. Dilation of the pupils (mydriasis). 4. Bronchodilation. 5. Inhibit salivation. 6. Decrease GI motility. 7. Stimulation of ejaculation. 8. Inhibit bladder contraction. 9. Stimulate glucose production and release. Fight-and-flight response: The changes experienced by the body during emergencies are referred to as the “fight and flight” response. These reactions are triggered both by direct sympathetic activation of the effector organs and by stimulation of the adrenal medulla to release epinephrine and lesser amounts of norepinephrine. Hormones released by the adrenal medulla directly enter the bloodstream and promote responses in effector organs that contain adrenergic receptors. The sympathetic nervous system tends to function as a unit and often discharges as a complete system, for example, during severe exercise or in reactions to fear. 3 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Accordingly, the sympathetic division has the property of adjusting in response to stressful situations, such as trauma, fear, hypoglycaemia, cold, and exercise. B) Functions of the parasympathetic nervous system The parasympathetic division is involved with maintaining homeostasis within the body. It is required for life, since it maintains essential bodily functions, such as digestion and elimination of wastes. The parasympathetic division usually acts to oppose or balance the actions of the sympathetic division and generally predominates the sympathetic system in “rest-and- digest” situations. Unlike the sympathetic system, the parasympathetic system never discharges as a complete system. If it did, it would produce massive, undesirable, and unpleasant symptoms, such as involuntary urination and defecation. Instead, parasympathetic fibres innervating specific organs such as the gut, heart, or eye are activated separately, and the system functions to affect these organs individually. So, the effect of parasympathetic output can be summarised in: 1- Pupil contraction (miosis). 2- Bronchoconstriction. 3- Stimulation of erection. 4- Stimulation tears and saliva secretion. 5- Decreasing heart rate and contractility. 6- Increasing the muscle motility and tone of the gastrointestinal system. Functions of the enteric nervous system (ENS) The enteric nervous system is a collection of neurons in the gastrointestinal tract that constitutes the “brain of the gut” and can function independently of 4 3rd Year Dental Students pharmacology Dr. Duaa Nidhal the central nervous system. This system controls the motility, exocrine and endocrine secretions, and microcirculation of the gastrointestinal tract. Functions of the somatic nervous system The somatic system is the part of the peripheral nervous system that is responsible for carrying motor and sensory information both to and from the central nervous system without the mediation of ganglia. This system is made up of nerves that connect to the skin, sensory organs, and all skeletal muscles. The system is responsible for nearly all voluntary muscle movements as well as for processing sensory information that arrives via external stimuli including hearing, touch, and sight. Figure 4 shows the main differences between autonomic and somatic nervous system. Figure 4: main differences between autonomic and somatic nervous system 5 3rd Year Dental Students pharmacology Dr. Duaa Nidhal The ANS requires sensory input from peripheral structures to provide information on the current state of the body. This feedback is provided by streams of afferent impulses, originating in the viscera and other autonomically innervated structures that travel to integrating centers in the CNS, such as the hypothalamus and spinal cord. These centers respond to the stimuli by sending out efferent reflex impulses via the ANS. This process of initiating an afferent impulse that travel to the CNS and replying by efferent impulse to get a response is called reflex arc (figure 5). Figure 5: Somatic and autonomic reflex arc Usually, most of the afferent impulses are involuntary translated into reflex responses. For example, a fall in blood pressure causes pressure-sensitive neurons (baroreceptors in the heart, vena cava, aortic arch, and carotid sinuses) to send fewer impulses to cardiovascular centres in the brain. This prompts a reflex response of increased sympathetic output to the heart and vasculature and decreased parasympathetic output to the heart, which results in a compensatory rise in blood pressure and tachycardia. According to the above explanation, the reflex arcs of the ANS comprise a sensory (or afferent) arm and a motor (or efferent or effector) arm. Neurotransmitters Neurotransmission in the ANS is an example of the more general process of chemical signalling between cells using neurotransmitters. Neurotransmitters are specific chemical signals that are released from nerve terminals to 6 3rd Year Dental Students pharmacology Dr. Duaa Nidhal establish the communication between nerve cells, and between nerve cells and effector organs. In spite of recognising more than 50 signals molecules (neurotransmitters) in the nervous system, just norepinephrine (and the closely related epinephrine), acetylcholine, dopamine, serotonin, histamine, glutamate, and γ-aminobutyric acid are the most commonly involved neurotransmitters in the actions of therapeutically useful drugs. Each type of neurotransmitters can bind with a specific receptor in order to give the biological desirable response. The primary chemical signals in the ANS are the acetylcholine and norepinephrine as they are involved in conducting wide variety functions in the CNS. The autonomic nerve fibres can be classified to cholinergic and adrenergic neurons based on the type of the released neurotransmitters whether they are acetylcholine or epinephrine and norepinephrine. Acetylcholine mediates the transmission of nerve impulses across autonomic ganglia in both the sympathetic and parasympathetic nervous systems. Transmission from the autonomic postganglionic nerves to the effector organs in the parasympathetic system, and a few sympathetic system organs also involve the release of acetylcholine (figure 6). In the somatic nervous system, transmission at the neuromuscular junction (the junction of nerve fibres and voluntary muscles) is also cholinergic. In the sympathetic system, norepinephrine mediates the transmission of nerve impulses from autonomic postganglionic nerves to effector organs except few sympathetic fibres, such as those involved in sweating, are cholinergic. 7 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Figure 6: Neurotransmitters Cholinergic agonists The cholinergic drugs act on receptors that are activated by acetylcholine (ACh). These receptors include nicotinic and muscarinic receptors and can be mainly recognised in sympathetic and parasympathetic nervous system and somatic nervous system as well (Figure 7). The two classes of receptor for Ach are defined on the basis of their preferential activation by the alkaloids nicotine and muscarine. 8 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Figure 7: Ach receptors muscarinic and nicotinic receptors, the nicotinic receptors located on autonomic ganglia (Nn subtype) and on neuromuscular junction on somatic nervous system (Nm subtype) Neurotransmission at cholinergic neurons Neurotransmission in cholinergic neurons involves six sequential steps: 1) synthesis, 2) storage, 3) release, 4) binding of ACh to a receptor, 5) degradation of the neurotransmitter in the synaptic cleft (that is, the space between the nerve endings and adjacent receptors located on nerves or effector organs), and 6) recycling of choline and acetate (figure 8) 9 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Figure 8: Ach synthesis 1.Synthesis of acetylcholine: Choline is transported from the extracellular fluid into the cytoplasm of the cholinergic neuron by an energy-dependent carrier system. Choline acetyltransferase catalyzes the reaction of choline with acetyl coenzyme A (CoA) to form ACh (an ester) in the cytosol. 2. Storage of acetylcholine in vesicles: ACh is packaged and stored into presynaptic vesicles. 3. Release of acetylcholine: When an action potential propagated at a nerve ending, voltagesensitive calcium channels on the presynaptic membrane open, causing an increase in the concentration of intracellular calcium. Elevated 10 3rd Year Dental Students pharmacology Dr. Duaa Nidhal calcium levels promote the fusion of synaptic vesicles with the cell membrane and the release of their contents into the synaptic space. 4.Binding to the receptor: ACh released from the synaptic vesicles diffuses across the synaptic space and binds its receptors. The postsynaptic cholinergic receptors on the surface of the effector organs are divided into two classes: muscarinic and nicotinic. Binding to a receptor leads to a biologic response within the cell, such as the initiation of a nerve impulse in a postganglionic fiber or activation of specific enzymes in effector cells. 5. Degradation of acetylcholine: The signal at the postjunctional effector site is rapidly terminated, because AChE (acetylcholine esterase) cleaves ACh to choline and acetate in the synaptic cleft. 6. Recycling of choline: Choline may be recaptured by a sodium-coupled uptake system that transports the molecule back into the neuron. There, it is acetylated into ACh that is stored until released by a subsequent action potential. CHOLINERGIC RECEPTORS (CHOLINOCEPTORS) Cholinoceptors can be classified into two types: muscarinic and nicotinic receptors. They are different mainly in their affinities for agent that mimic the action of ACh (cholinomimetic agents). 1- Muscarinic receptors: It is one of the G protein–coupled receptors that have high affinity to bind with muscarine (an alkaloid that is present in certain poisonous mushrooms) and ACh but low affinity to bind with nicotine. Five sub-classes are recognised for this receptor family; however, only M1, M2, and M3 receptors have been functionally characterised. a- Locations of muscarinic receptors 11 3rd Year Dental Students pharmacology Dr. Duaa Nidhal b- Muscarinic agonists: Pilocarpine is an example of a nonselective muscarinic agonist used in clinical practice to treat xerostomia and glaucoma. Attempts are currently underway to develop muscarinic agonists and antagonists that are directed against specific receptor subtypes. M1 receptor agonists are being investigated for the treatment of Alzheimer’s disease. 2- Nicotinic receptors These receptors, in addition to binding ACh, also recognise nicotine but show only a weak affinity for muscarine. Nicotine at low concentration stimulates the receptor, whereas nicotine at high concentration blocks the receptor. The nicotinic receptor functions as a ligand-gated ion channel. Location: Nicotinic receptors are located in the CNS, the adrenal medulla, autonomic ganglia, and the neuromuscular junction (NMJ) in skeletal muscles. Those at the NMJ are sometimes designated NM, and the others, NN. The nicotinic receptors of autonomic ganglia differ from those of the NMJ. For example, ganglionic receptors are selectively blocked by mecamylamine, whereas NMJ receptors are specifically blocked by atracurium. 12 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Below is a table summarizing the function of each cholinergic receptor DIRECT-ACTING CHOLINERGIC AGONISTS Definition: Materials that mimic the effects of ACh by binding directly to cholinoceptors (muscarinic or nicotinic). Types: 1) endogenous choline esters, which include ACh and synthetic esters of choline, such as carbachol and bethanechol. 2) Naturally occurring alkaloids, such as nicotine and pilocarpine. The main advantage of this group of drugs that have a longer duration of action than ACh. The more therapeutically useful drugs (pilocarpine and bethanechol) preferentially bind to muscarinic receptors and are sometimes referred to as muscarinic agents. As a group, the directacting agonists demonstrate little specificity in their actions, which limits their clinical usefulness. Acetylcholine Acetylcholine is a quaternary ammonium compound; hence it cannot penetrate membranes. In spite of considering the ACh as a neurotransmitter of parasympathetic and somatic nerves as well as autonomic ganglia, it lacks therapeutic importance because of its pluralism of actions and its rapid inactivation by the cholinesterases. ACh has both muscarinic and nicotinic activity. Its actions include the following: 1- Decrease in heart rate and cardiac output: The actions of ACh on the heart imitate the effects of vagal stimulation. For example, if injected 13 3rd Year Dental Students pharmacology Dr. Duaa Nidhal intravenously, ACh produces a brief decrease in cardiac rate (negative chronotropy) and stroke volume as a result of a reduction in the rate of firing at the sinoatrial (SA) node. 2- Decrease in blood pressure: As a result of ACh injection, vasodilation and lowering of blood pressure can be observed. This is due to an indirect mechanism of action because the ACh activates M3 receptors that found on endothelial cells lining the smooth muscles of blood vessels. This leads to produce a nitric oxide that act as a vasodilator from arginine. In the absence of administered cholinergic agents, the vascular cholinergic receptors have no known function, because ACh is never released into the blood in significant quantities. Atropine blocks these muscarinic receptors and prevents ACh from producing vasodilation. 3- Other actions: ACh administration can stimulate: a- Salivary secretion stimulates intestinal secretions and motility. b- b- Bronchiolar secretions. c- Urination. Moreover, ACh causes miosis (marked constriction of the pupil). Accordingly, ACh (1% solution) is instilled into the anterior chamber of the eye to produce miosis during ophthalmic surgery. Therapeutic uses of direct-acting cholinergic agonists: bethanechol is used to stimulate the atonic bladder, particularly in postpartum or postoperative, nonobstructive urinary retention Carbachol as a miotic agent to treat glaucoma by causing pupillary contraction and a decrease in intraocular pressure. Pilocarpine is used to treat glaucoma and is the drug of choice in the emergency lowering of intraocular pressure in glaucoma. It is also beneficial in promoting salivation in patients with xerostomia (dry mouth) resulting from irradiation therapy of the head and neck cancer or due to Sjogren’s syndrome 14 3rd Year Dental Students pharmacology Dr. Duaa Nidhal (an autoimmune disease in which the moisture-producing glands of the body are affected causing mainly symptoms of dry eyes and dry mouth). Adverse effects of Ach and other cholinergic agonists: causes the effects of generalized cholinergic stimulation. Bronchospasm and increase secretions. GI: nausea, vomiting, and diarrhea. Miosis. Urinary urgency. Sweating (diaphoresis) and salivation. Pilocarpine can enter the brain (because it’s a tertiary amine (unionized)) and cause CNS disturbances. Poisoning with this agent is characterized by exaggeration of various parasympathetic effects. To counteract the poisoning effect of the pilocarpine and Bethanechol, Parenteral atropine, at doses that can cross the blood–brain barrier, is administered to counteract the toxicity of the cholinergic material. INDIRECT-ACTING CHOLINERGIC AGONISTS (ANTICHOLINESTERASE AGENTS (REVERSIBLE)) ACh is uaually deactivated by the AChE (Acetylcholine esterase), which is an enzyme that specifically cleaves ACh to acetate and choline. It can be found at both pre- and postsynaptically in the nerve terminal where it is membrane bound. Accordingly, inhibition of AchE can indirectly provide a cholinergic action by preventing the degradation of ACh. This results in an accumulation of ACh in the synaptic space. This process can be carried out by using the anticholinesterase agents or cholinesterase inhibitors. These drugs can provoke a response at all cholinoceptors in the body, including both 15 3rd Year Dental Students pharmacology Dr. Duaa Nidhal muscarinic and nicotinic receptors of the ANS, as well as at the NMJ and in the brain. Therapeutic uses of acetylcholinesterase inhibitors (reversible) Edrophonium, pyridostigmine, and ambenonium: They are used in the diagnosis and management of myasthenia gravis, which is an autoimmune disease caused by antibodies to the nicotinic receptor at NMJs. This causes their degradation, making fewer receptors available for interaction with the neurotransmitter. Physostigmine It increases intestinal and bladder motility, which serve as its therapeutic action in atony of either organ. used to treat glaucoma, but pilocarpine is more effective. as an antidote for drugs with anticholinergic actions. Neostigmine used to stimulate the bladder and GI tract. as an antidote for tubocurarine and other competitive neuromuscularblocking agents. also used to treat myasthenia gravis. donepezil, rivastigmine, and galantamine Patients with Alzheimer disease have a deficiency of cholinergic neurons in the CNS. This observation led to the development of anticholinesterases as possible remedies for the loss of cognitive function. Despite the ability of donepezil, rivastigmine, and galantamine to delay the progression of Alzheimer disease, none can stop its progression. 16 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Adverse effects of acetylcholinesterase inhibitors (reversible): Adverse effects include those of generalized cholinergic stimulation, such as salivation, flushing, decreased blood pressure, nausea, abdominal pain, diarrhea, and bronchospasm. Inhibition of AChE at the skeletal NMJ causes the accumulation of ACh and, ultimately, results in paralysis of skeletal muscle. Physostigmine can enter and stimulate the cholinergic sites in the CNS. The effects on the CNS may lead to convulsions when high doses are used. Bradycardia and a fall in cardiac output may also occur. INDIRECT-ACTING CHOLINERGIC AGONISTS (ANTICHOLINESTRASE AGENTS (IRREVERSIBLE)) A number of synthetic organophosphate compounds have the capacity to bind covalently to AChE. The result is a long-lasting increase in ACh at all sites where it is released. Many of these drugs are extremely toxic and were developed by the military as nerve agents. Related compounds, such as parathion and malathion, are used as insecticides. Table: Summary of echothiophate actions, therapeutic uses and its adverse effect. 17 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Cholinergic Antagonists Cholinergic antagonist is a general term for agents that bind to cholinoceptors (muscarinic or nicotinic) and prevent the effects of acetylcholine (ACh) and other cholinergic agonists. There are three types of cholinergic antagonist drugs, which are: 1- Antimuscarinic agents (anticholinergic drugs) block muscarinic receptors, causing inhibition of muscarinic functions. Because they do not block nicotinic receptors, the anticholinergic drugs (more precisely, antimuscarinic drugs) have little or no action at skeletal neuromuscular junctions (NMJs). 2- Ganglionic blockers (specifically act on the nicotinic receptors of both parasympathetic and sympathetic autonomic ganglia) The neuromuscular-blocking agents (mostly nicotinic antagonists), which block cholinergic transmission between motor nerve endings and the nicotinic receptors on the skeletal muscle 1- Atropine (antimuscarinic agents): It is an alkaloid with a high affinity for muscarinic receptors. It binds competitively and prevents ACh from binding to those sites. Atropine acts both centrally and peripherally. Its general actions last about 4 hours, except when placed topically in the eye, where the action may last for days. Neuroeffector organs have varying sensitivity to atropine. Effects: CNS: confusion, delirium. Decrease GI motility and acid secretions without interfering with hydrochloric secretion. 18 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Increase heart rate at high doses, i.e. higher than (0.5 mg). At low doses slight decrease in heart rate: At low doses, the predominant effect is a slight decrease in heart rate. This effect results from blockade of the M1 receptors on the inhibitory prejunctional (or presynaptic) neurons, thus permitting increased ACh release. Higher doses of atropine cause a progressive increase in heart rate by blocking the M2 receptors on the sinoatrial node Decrease body secretions like saliva (xerostomia), bronchial secretions, and sweat (elevate body temperature). Mydriasis (cycloplegic to permits the measurement of refractive errors without interference by the accommodative capacity of the eye). Therapeutic uses: As mydriatic and cycloplegic: Atropine is used topically for producing mydriasis and cycloplegia. The action of atropine lasts 7–10 days. As preanaesthetic medication: Atropine is used prior to the administration of general anaesthetics: To prevent vagal bradycardia during anaesthesia. To prevent laryngospasm by decreasing respiratory secretions. Antisecretory agent to block the secretions in the upper and lower respiratory tracts before surgery. Anticholinergics are useful as antispasmodics in dysmenorrhoea, intestinal and renal colic. Poisoning: a. In organophosphorous poisoning, atropine is the life-saving drug. b. In some types of mushroom poisoning, atropine is the drug of choice. c. Atropine is used in curare poisoning with neostigmine to counteract the muscarinic effects of neostigmine. As vagolytic: Atropine is used to treat sinus bradycardia and partial heart block due to increased vagal activity. 19 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Side effects: Blurred vision, decrease secretions, hyperthermia, constipation, urinary retention, delirium, and hallucinations. Scopolamine is another antagonist used for motion sickness. Ipratropium used as inhaler to decrease bronchoconstriction and bronchial secretions in COPD (chronic obstructive pulmonary disease) and asthma. 2- Nicotine (Ganglionic blockers): although nicotine considers as an agonist at nicotinic receptors, but at higher dose it blocks the autonomic ganglia (figure 9). Nicotine produces initial stimulation and varying degrees of subsequent block through a mechanism analogous to that of succinylcholine (see later). Nicotine is a component of cigarette smoke, is a poison with many undesirable actions. However, it can be used in a controlled way to help in giving up smoking. It is found in more than one pharmaceutical dosage forms like sublingual tablets, lozenges and as chewing gum. Its action can be summarised in these points: Increasing the blood pressure and cardiac rate and at higher doses, the blood pressure falls because of ganglionic blockade, and activity in both the GI tract and bladder musculature ceases 20 3rd Year Dental Students pharmacology Dr. Duaa Nidhal Figure 9: position of nicotinic receptor in autonomic ganglia 3- The neuromuscular-blocking agents: These drugs block cholinergic transmission between motor nerve endings and the nicotinic receptors on the skeletal muscle. They possess some chemical similarities to ACh, and they act either as antagonists (nondepolarising type) or as agonists (depolarising type) at the receptors on the endplate of the NMJ. Neuromuscular blockers are clinically useful during surgery to facilitate tracheal intubation and provide complete muscle relaxation at lower anaesthetic doses, allowing for more rapid recovery from anesthesia and reducing postoperative respiratory depression. 21 3rd Year Dental Students pharmacology Dr. Duaa Nidhal 1- Nondepolarising (competitive) blockers: At low doses: Nondepolarising agents competitively block ACh at the nicotinic receptors. That is, they compete with ACh at the receptor without stimulating it. Thus, these drugs prevent depolarisation of the muscle cell membrane and inhibit muscular contraction. On the other hand, on high doses, these drugs can lead to complete blockade and the muscle does not respond to direct electrical stimulation. All neuromuscular-blocking agents are injected intravenously or occasionally intramuscularly since they are not effective orally. In general, these agents are safe with minimal side effects; however, they can rarely cause bronchospasm. 2- Depolarising agents: Depolarising blocking agents work by depolarising the plasma membrane of the muscle fibre, similar to the action of ACh. However, these agents are more resistant to degradation by acetylcholinesterase (AChE) and can thus more persistently depolarise the muscle fibres. Succinylcholine is the only depolarising muscle relaxant in use today. Succinylcholine attaches to the nicotinic receptor and acts like ACh to depolarise the junction. This leads to a transient twitching of the muscle. Continued binding of the depolarising agent renders the receptor incapable of transmitting further impulses leading to flaccid paralysis. Therapeutically, succinylcholine (which is administered IV) is useful when rapid endotracheal intubation is required during the induction of anaesthesia. The main side effects of this drug are the hyperthermia, apnea and hyperkalaemia. 22